Main menu

London Calling 2023: Potential use of nanopore sequencing in clinical cancer genomics


Advances in sequencing technologies have transformed our understanding of cancer and ushered in a new era for cancer research. The Personalized OncoGenomics (POG) program is a prospective precision medicine initiative integrating whole-genome and transcriptome analysis (WGTA) into the clinical care of people with advanced cancers in British Columbia, Canada. In a sub-study of our larger cohort, we performed long-read Oxford Nanopore sequencing on 178 patient’s samples, in order to address some limitations we have noted with short-read sequencing. Comparison of these data sets has demonstrated situations where we now plan to apply nanopore sequencing prospectively within POG.

Authors: Janessa Laskin

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag